Gene Transfer Clinical Trial for Infantile and Late Infantile Krabbe Disease Treated Previously With HSCT

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

February 3, 2023

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2026

Conditions
Krabbe Disease
Interventions
BIOLOGICAL

FBX-101

A replication-deficient adeno-associated virus gene transfer vector expressing the human galactocerebrosidase (GALC) cDNA will be delivered one-time through a venous catheter inserted into a peripheral limb vein.

Trial Locations (3)

27705

Duke University Medical Center, Durham

48109

University of Michigan Hospitals - Michigan Medicine, Ann Arbor

92868

Children's Hospital of Orange County (CHOC), Orange

Sponsors
All Listed Sponsors
lead

Forge Biologics, Inc

INDUSTRY